<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134081</url>
  </required_header>
  <id_info>
    <org_study_id>06-PER-002-CTX Bio Adjunct</org_study_id>
    <nct_id>NCT01134081</nct_id>
  </id_info>
  <brief_title>Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts</brief_title>
  <official_title>Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Organogenesis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational research study is to understand more about wound healing of
      gum tissue. This study was the biomarker study of a small cohort of study participants
      derived from NCT01547962 (completed). Two surgical sites of each patient were randomly
      selected to receive CelTx™ as a donor material in one site and conventional autograft using
      keratinized tissue from the palate as the donor material at the contralateral (opposite side)
      site. Fluids collected from between a tooth and the gum and directly from wounds contain
      proteins that occur in different levels as the wound healing process proceeds. In this
      research study wound fluid will be collected from the donor palate site (roof of your mouth)
      and the treated sites on your gum before and after placement of CelTx and conventional
      treatment (tissue from the roof of your mouth) to measure which proteins and how much of each
      are present during the first 4 weeks of wound healing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a clinical trial designed to evaluate the safety and effectiveness of rhPDGF-BB to promote
      soft and hard tissue engineering of the periodontium, the subjects provided gingival
      crevicular fluid (GCF) or periodontal wound fluid (WF) and the results demonstrated
      contrasting inducible expression patterns of PDGF-AB, VEGF, and ICTP during periodontal
      healing [17, 24, 25]. However, little is known regarding the release of these molecules into
      local periodontal wound fluid during tissue-engineered grafts.

      The aim of this study is to determine the presence and influence of angiogenic biomarkers,
      such as PDGF, VEGF, and FGF, involved in the wound healing process of tissue engineered
      grafts in the treatment of subjects (with recession-type defects) who have an insufficient
      zone of attached gingival associated with at least two nonadjacent teeth.

      STUDY OBJECTIVES The purpose of this pilot study is to compare the expression of angiogenic
      biomarkers involved in the wound healing process of 2 different periodontal surgical
      approaches: 1) CelTx™ (living bilayered cell therapy product) and 2) free gingival grafts
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in Angiogenic Biomarkers</measure>
    <time_frame>5 time-points: pre-surgical, week(s) 1, 2, 3 and 4</time_frame>
    <description>Within-subject difference between the concentrations at the CelTX and Free Gingival Graft areas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in Angiogenic Biomarkers: PDGF-BB</measure>
    <time_frame>5 time-points: pre-surgical, week(s) 1, 2, 3 and 4</time_frame>
    <description>Within-subject difference between the concentrations at the CelTX and Free Gingival Graft areas</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Gingival Recession</condition>
  <arm_group>
    <arm_group_label>CelTx™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Living bilayered cell therapy product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free Gingival Grafts</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Harvested tissue from palate</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CelTx™</intervention_name>
    <description>CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.</description>
    <arm_group_label>CelTx™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Free Gingival Graft</intervention_name>
    <description>Harvested tissue from palate</description>
    <arm_group_label>Free Gingival Grafts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has signed informed consent to participate in Organogenesis Clinical Protocol
             06-PER-002-CTX.

          -  Subject has signed informed consent to participate in this adjunct bio-marker study.

          -  Subject is willing to comply with the additional study visits at weeks 2 and 3 as
             required by this study.

        Exclusion Criteria:

        - Subject requires antibiotic prophylaxis for routine dental procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Neiva, DDS, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michigan Center for Oral Health Research</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Morelli T, Neiva R, Nevins ML, McGuire MK, Scheyer ET, Oh TJ, Braun TM, Nör JE, Bates D, Giannobile WV. Angiogenic biomarkers and healing of living cellular constructs. J Dent Res. 2011 Apr;90(4):456-62. doi: 10.1177/0022034510389334. Epub 2011 Jan 19.</citation>
    <PMID>21248359</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <results_first_submitted>September 27, 2010</results_first_submitted>
  <results_first_submitted_qc>June 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 18, 2017</results_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>William Giannobile</investigator_full_name>
    <investigator_title>Chair, Department of Periodontics &amp; Oral Medicine Najjar Endowed Professor of Dentistry and Biomedical Engineering</investigator_title>
  </responsible_party>
  <keyword>gum</keyword>
  <keyword>recession</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gingival Recession</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>44 subjects were enrolled. All 44 subjects participated in both arms/groups for a total of 88 surgical sites. 2 surgical sites of each patient were randomly selected to receive LCC as a donor material in 1 site and a conventional autograft using keratinized tissue from the palate as the donor material at the contralateral site.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CelTx™ &amp; Free Gingival Grafts</title>
          <description>CelTx™: Living bilayered cell therapy product Free Gingival Grafts: Harvested tissue from palate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CelTx™ &amp; Free Gingival Grafts</title>
          <description>CelTx™: Living bilayered cell therapy product Free Gingival Grafts: Harvested tissue from palate</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Surgical sites</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Angiogenic Biomarkers</title>
        <description>Within-subject difference between the concentrations at the CelTX and Free Gingival Graft areas</description>
        <time_frame>5 time-points: pre-surgical, week(s) 1, 2, 3 and 4</time_frame>
        <population>44 subjects were enrolled. All 44 subjects participated in both arms/groups for a total of 88 surgical sites. 2 surgical sites of each patient were randomly selected to receive LCC as a donor material in 1 site and a conventional autograft using keratinized tissue from the palate as the donor material at the contralateral site.</population>
        <group_list>
          <group group_id="O1">
            <title>CelTx™</title>
            <description>Living bilayered cell therapy product</description>
          </group>
          <group group_id="O2">
            <title>Free Gingival Grafts</title>
            <description>Harvested tissue from palate</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Angiogenic Biomarkers</title>
          <description>Within-subject difference between the concentrations at the CelTX and Free Gingival Graft areas</description>
          <population>44 subjects were enrolled. All 44 subjects participated in both arms/groups for a total of 88 surgical sites. 2 surgical sites of each patient were randomly selected to receive LCC as a donor material in 1 site and a conventional autograft using keratinized tissue from the palate as the donor material at the contralateral site.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Surgical sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Surgical sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VEGF-pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread=".07"/>
                    <measurement group_id="O2" value=".69" spread=".15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VGEF-week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread=".24"/>
                    <measurement group_id="O2" value=".67" spread=".12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VGEF-week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".28" spread=".06"/>
                    <measurement group_id="O2" value=".16" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VGEF-week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".14" spread=".03"/>
                    <measurement group_id="O2" value=".11" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VGEF-week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".1" spread=".02"/>
                    <measurement group_id="O2" value=".06" spread=".02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiogenin (ANG)-pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread=".97"/>
                    <measurement group_id="O2" value="5.60" spread=".82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiogenin (ANG)-week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.32" spread="1.26"/>
                    <measurement group_id="O2" value="7.09" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiogenin (ANG)-week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread=".65"/>
                    <measurement group_id="O2" value="2.56" spread=".54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiogenin (ANG)-week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread=".30"/>
                    <measurement group_id="O2" value="1.85" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiogenin (ANG)-week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread=".23"/>
                    <measurement group_id="O2" value="1.58" spread=".38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8-pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread=".21"/>
                    <measurement group_id="O2" value="1.31" spread=".22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8-week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread=".76"/>
                    <measurement group_id="O2" value="4.44" spread=".72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8-week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".58" spread=".15"/>
                    <measurement group_id="O2" value=".31" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8-week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".19" spread=".07"/>
                    <measurement group_id="O2" value=".15" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8-week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".11" spread=".03"/>
                    <measurement group_id="O2" value=".11" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF-2-pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".65" spread=".12"/>
                    <measurement group_id="O2" value=".72" spread=".17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF-2-week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread=".51"/>
                    <measurement group_id="O2" value=".85" spread=".17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF-2-week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".4" spread=".11"/>
                    <measurement group_id="O2" value=".34" spread=".11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF-2-week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".20" spread=".06"/>
                    <measurement group_id="O2" value=".29" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF-2-week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".18" spread=".07"/>
                    <measurement group_id="O2" value=".24" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiostatin (ANT)-pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6728.08" spread="1996.62"/>
                    <measurement group_id="O2" value="7931.32" spread="2813.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiostatin (ANT)-week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12330.29" spread="3523.17"/>
                    <measurement group_id="O2" value="3871.60" spread="782.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiostatin (ANT)-week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3059.87" spread="1037.32"/>
                    <measurement group_id="O2" value="1524.59" spread="654.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiostatin (ANT)-week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1668.22" spread="605.07"/>
                    <measurement group_id="O2" value="1682.54" spread="453.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiostatin (ANT)-week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1527.26" spread="507.75"/>
                    <measurement group_id="O2" value="1183.51" spread="441.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-1-pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.14" spread="1.09"/>
                    <measurement group_id="O2" value="8.56" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-1-week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.63" spread="1.68"/>
                    <measurement group_id="O2" value="14.68" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-1-week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.81" spread="1.42"/>
                    <measurement group_id="O2" value="5.60" spread=".93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-1-week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread=".94"/>
                    <measurement group_id="O2" value="3.98" spread=".77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-1-week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" spread=".72"/>
                    <measurement group_id="O2" value="3.58" spread=".73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-2-pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="1.51"/>
                    <measurement group_id="O2" value="11.11" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-2-week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.13" spread="3.47"/>
                    <measurement group_id="O2" value="9.91" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-2-week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread=".95"/>
                    <measurement group_id="O2" value="2.41" spread=".77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-2-week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" spread=".70"/>
                    <measurement group_id="O2" value="1.43" spread=".46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-2-week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread=".52"/>
                    <measurement group_id="O2" value=".93" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF-pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.48" spread="19.53"/>
                    <measurement group_id="O2" value="50.27" spread="13.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF-week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.85" spread="21.57"/>
                    <measurement group_id="O2" value="102.02" spread="24.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF-week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.20" spread="21.38"/>
                    <measurement group_id="O2" value="93.81" spread="20.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF-week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.16" spread="20.76"/>
                    <measurement group_id="O2" value="86.16" spread="18.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF-week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.81" spread="16.76"/>
                    <measurement group_id="O2" value="80.34" spread="16.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10-pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".78" spread=".36"/>
                    <measurement group_id="O2" value=".21" spread=".07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10-week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" spread=".02"/>
                    <measurement group_id="O2" value=".5" spread=".45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10-week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".39" spread=".29"/>
                    <measurement group_id="O2" value=".08" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10-week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".18" spread=".12"/>
                    <measurement group_id="O2" value=".02" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10-week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".01"/>
                    <measurement group_id="O2" value=".01" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Differences in Angiogenic Biomarkers: PDGF-BB</title>
        <description>Within-subject difference between the concentrations at the CelTX and Free Gingival Graft areas</description>
        <time_frame>5 time-points: pre-surgical, week(s) 1, 2, 3 and 4</time_frame>
        <population>44 subjects were enrolled. All 44 subjects participated in both arms/groups for a total of 88 surgical sites. 2 surgical sites of each patient were randomly selected to receive LCC as a donor material in 1 site and a conventional autograft using keratinized tissue from the palate as the donor material at the contralateral site.</population>
        <group_list>
          <group group_id="O1">
            <title>CelTx™</title>
            <description>Living bilayered cell therapy product
CelTx™: CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.</description>
          </group>
          <group group_id="O2">
            <title>Free Gingival Grafts</title>
            <description>Harvested tissue from palate
Free Gingival Graft: Harvested tissue from palate</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Angiogenic Biomarkers: PDGF-BB</title>
          <description>Within-subject difference between the concentrations at the CelTX and Free Gingival Graft areas</description>
          <population>44 subjects were enrolled. All 44 subjects participated in both arms/groups for a total of 88 surgical sites. 2 surgical sites of each patient were randomly selected to receive LCC as a donor material in 1 site and a conventional autograft using keratinized tissue from the palate as the donor material at the contralateral site.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.59" spread="3.06"/>
                    <measurement group_id="O2" value="9.73" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.82" spread="20.41"/>
                    <measurement group_id="O2" value="28.92" spread="13.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" spread="3.03"/>
                    <measurement group_id="O2" value="2.33" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread=".83"/>
                    <measurement group_id="O2" value="1.01" spread=".44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".86" spread=".43"/>
                    <measurement group_id="O2" value=".87" spread=".50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>No adverse or serious adverse events were observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>CelTx™</title>
          <description>Living bilayered cell therapy product</description>
        </group>
        <group group_id="E2">
          <title>Free Gingival Graft</title>
          <description>Harvested tissue from palate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although the present study compared the differences in angiogenic biomarker expression between LCC and autograft, it is important to understand that both LCC and autograft heal by two different healing processes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. William Giannobile</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734 763 2105</phone>
      <email>wgiannob@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

